Genomic and immune characteristics of EGFR subtypes in non-small cell lung cancer (NSCLC)


J. Nicholas Bodor, 1 Joanne Xiu, 2 Vinicius Ernani, 3 Supreet Kaur, 4 Hirva Mamdani, 5 Pavel Brodskiy, 2 Sai Hong I. Ou, 6 Patrick C. Ma, 7 Margie L. Clapper, 1 W. Michael Korn, 2 Joseph Treat 1


 ●While EGFR-mutant NSCLC tumors generally are resistant to PD-1/PD-L1 inhibitors, a small subset of patients can have durable responses.1,2

●EGFR tumors demonstrate significant molecular heterogeneity, especially with respect to mutation subtypes.

●A small number of studies suggest better outcomes with checkpoint inhibitors in patients with tumors possessing uncommon EGFR mutations3or L858R mutations,1however data on this are still limited.

●There is a lack of clarity on the genomic and immune profiles of EGFR mutation subtypes, and further elucidation of this may help optimally identifying patients likely to respond to immune-based therapies.

Download Publication